Analyst Update: Bio Blast Pharma, Centene, Goldcorp

Analysts adjusted their ratings on Bio Blast Pharma Ltd (NASDAQ:ORPN), Centene Corp (NYSE:CNC), and Goldcorp Inc. (USA) (NYSE:GG)

Jun 15, 2015 at 12:23 PM
facebook twitter linkedin


Analysts are weighing in today on biopharmaceutical firm Bio Blast Pharma Ltd (NASDAQ:ORPN), healthcare concern Centene Corp (NYSE:CNC), and gold producer Goldcorp Inc. (USA) (NYSE:GG). Here's a quick roundup of today's brokerage notes on ORPN, CNC, and GG.

  • Drugmakers are in the bullish crosshairs of brokerage firms today. For ORPN, this meant a price-target hike to $25 from $18 at Roth Capital, which expressed confidence the company's Phase III trial of its experimental muscular dystrophy drug -- which began today -- will wrap up sooner rather than later. The new price target, which resides in never-before-seen territory, has shares of ORPN up 27% at $7.31 -- and back in the black on a year-to-date basis. Widening the scope reveals today's optimistic outlook just echoes the withstanding sentiment. Roughly 0.1% of Bio Blast Pharma Ltd's float is sold short, and both analysts covering the shares maintain a "strong buy" recommendation.

  • CNC has received a number of bullish brokerage notes since the firm boosted its full-year forecast last Thursday morning. In fact, over the weekend, no fewer than six analysts upwardly revised their price targets. Included in the bunch was Barclays, which raised its target price to $88 from $84, as well as Cantor and Leerink, which both boosted their respective price targets to $85. Against this backdrop, CNC is up 3.7% today at $78.18, and fresh off an all-time peak of $78.27. Additional upbeat analyst attention could have the shares adding to their 50% year-to-date gain. More than half of those covering Centene Corp maintain a lukewarm "hold" recommendation, while the average 12-month price target of $78.20 is in line with current trading levels.

  • RBC cut its outlook on GG to "sector perform" from "outperform" and its price target to $21 from $24 -- sending the shares to a new six-year low of $16.59 out of the gate. At last check, the stock was down 0.9% at $16.70, bringing its 2015 deficit to 9.8%. Option traders have been rolling the dice on a rebound, though, by buying to open calls over puts at an accelerated clip in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Goldcorp Inc.'s 10-day call/put volume ratio of 9.05 sits just 7 percentage points from an annual high.
 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners